Bergen

• A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative … Ended recruitment
  2024-511796-15-00 5 2024-10-16 Acetylcholine Receptor Binding Antibody Seronegative Generalized Myast
• The p53 breast cancer trial Ended recruitment
  2024-515135-29-00 4 2024-10-12 breast cancer
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves … Ended recruitment
  2022-502640-12-01 9 2024-09-27 Non-small cell lung cancer (NSCLC)
• The role of sonoporation-enhanced treatment in patients with inoperable pancreatic cancer Ended recruitment
  2024-512176-35-00 4 2024-09-27 Pancreatic cancer
• RElapse from Mrd Negativity As iNdication for Treatment Ended recruitment
  2023-510215-18-00 10 2024-09-26 Multiple myeloma
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended recruitment
  2022-500100-21-01 4 2023-09-11 Follicular lymphoma
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended recruitment
  2023-508462-15-00 10 2023-04-27 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• Antiviral treatment for long covid. Ended recruitment
  2023-510337-29-00 5 2023-04-11 Virus Diseases
• (Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended recruitment
  2022-500637-80-00 5 2023-03-28 gastrointestinal stromal tumor
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult … Ended recruitment
  2022-500861-29-00 5 2023-01-12 Relapsed or Refractory Multiple Myeloma (RRMM)
• A double-blind randomized placebo-controlled four-arm trial to assess the efficacy of oral bicarbonate and intravenous butylscopolamine brom … Ended recruitment
  2024-511848-55-00 5 2023-01-03 childbirth
• METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the Common pMMR/MSS Type of Large Bowel Cancer Spread to Other Organ … Ended recruitment
  2022-500027-76-00 4 2022-10-05 Colorectal cancer
• A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥16 years of age with … Ended recruitment
  2024-511990-31-00 5 2022-06-28 Fabry Disease
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• Daratumumab in ME/CFS Ended recruitment
  2024-512500-19-00 4 2022-04-29 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
• New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients Ended recruitment
  2023-510054-16-00 4 2022-04-26 Primary Sjogren's syndrome
• Open-Label and Long-term Extension Study with Dersimelagon (MT-7117) in Subjects with EPP or XLP Ended recruitment
  2024-514466-38-00 5 2022-04-19 Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
• Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with exten … Ended recruitment
  2023-505514-15-00 5 2022-01-11 Small-cell lung cancer, extensive stage

Showing 145–168 of 235 trials